¥È¥Ã¥× > ¥¸¥ã¥ó¥ë¤«¤éõ¤¹ > ¥¸¥ã¡¼¥Ê¥ë > ÆüËܸƵ۴ï³Ø²ñ»ï > ÆüËܸƵ۴ï³Ø²ñ»ï Âè9´¬Âè4¹æ
ȯ¹Ô¸µ¤«¤éõ¤¹ > ÆüËܸƵ۴ï³Ø²ñ > ÆüËܸƵ۴ï³Ø²ñ»ï Âè9´¬Âè4¹æ

ÆüËܸƵ۴ï³Ø²ñ»ï Âè9´¬Âè4¹æ¡Ê2020ǯ7·î¹æ¡Ë

ȯ¹Ô¡§ÆüËܸƵ۴ï³Ø²ñ
ÊÔ½¸¡¦´Æ½¤¡§ÆüËܸƵ۴ï³Ø²ñÏÂʸ»ïÊÔ½¸°Ñ°÷²ñ
ISSN¡§2186-5884
¥µ¥¤¥º A4ÊÑ·Á¡¿¥Ú¡¼¥¸¿ô 82¥Ú¡¼¥¸
2020ǯ7·î10Æüȯ¹Ô

¢¨¼õÃíÈÎÇä¤È¤Ê¤ê¤Þ¤¹°Ù¡¢Æþ¶â³Îǧ¸å¡¢È¯Á÷¤Þ¤Ç¤Ë10Æü¤Û¤É¤ª»þ´Ö¤ò¤¤¤¿¤À¤­¤Þ¤¹¡£
¢¨¡ÖÆüËܸƵ۴ï³Ø²ñ»ï¡×¤Îǯ´Ö¹ØÆɤò¤´´õ˾¤ÎÊý¤Ï¤³¤Á¤é¤Ø¤´Ï¢Íí¤¯¤À¤µ¤¤¡£


Ìܼ¡

¸¶Ãø

¿··¿¥³¥í¥Ê¥¦¥¤¥ë¥¹´¶À÷¾É¿ÇÎŤˤª¤±¤ë¸ÆµÛ´ïÆâ²Ê°å»Õ¤Î³èÆ°¼ÂÂ֤˴ؤ¹¤ë¥¢¥ó¥±¡¼¥ÈÄ´ºº·ë²Ì
³ùÅÄ¡¡·¼Í¤¡¤º£Ìî¡¡¡¡Å¯¡¤¶â»Ò¡¡¡¡ÌÔ¡¤Ê¡±Ê¡¡¶½°í¡¤Ä¹Ã«Àî¹¥µ¬¡¤²£»³¡¡¾´¿Î

¸¶Ãø

Åö±¡¤Ë¤ª¤±¤ë¥¤¥ó¥Õ¥ë¥¨¥ó¥¶Æþ±¡¿ÇÎÅ¡¤¤ª¤è¤Ó¹³¥¤¥ó¥Õ¥ë¥¨¥ó¥¶Ìô¤Î±Æ¶Á
¸åÆ£¡¡·ò°ì¡¤Ë±»³¡¡°¼Çµ¡¤Ìî¹Â¡¡¡¡³Ù¡¤Ä¹Ã«Àî¹À°ì¡¤¿¼ÅÄ¡¡´²»Ò¡¤Ã漡¡ÊÝÀ¶¡¤ËÌ¡¡¡¡±ÑÉס¤¾¾²¼¤á¤°¤ß

¸¶Ãø

COPD´µ¼Ô¤ËÂФ¹¤ëadvance care planning¤È¥³¡¼¥É¥¹¥Æ¡¼¥¿¥¹
¿ÀµÜ¡¡ÂçÊ塤ÌðÅç¡¡¹äÍΡ¤ÌÚ¼¡¡¡¡Ë¾¡¤º´Æ£¡¡¹¬Í¤¡¤À¸Êý¡¡¡¡ÃÒ¡¤¾±»Ê¡¡¡¡½ß¡¤¹â¶¶¡¡¡¡ÍΡ¤ÅÏÊÕ¡¡¡¡ÍÎ

¾ÉÎã

¥²¥Õ¥£¥Á¥Ë¥Ö¤òºÆÅêÍ¿¤·15ǯĹ´üÀ¸Â¸¤·¤Æ¤¤¤ë¿Ê¹ÔÇÙÁ£´â¤Î1Îã
Çß²¼¡¡²ñÈþ¡¤»³º¬¿¿Í³¹á¡¤´äÉô¡¡Ä¾Èþ¡¤¸þÅÄ¡¡¸­»Ô¡¤·¦ÅÄ¡¡Å¯Ì顤²£»³¡¡¾´¿Î

¾ÉÎã

¿ȯÇÙ¶õƶÉÂÊѤòÄ褷¤¿G-CSF»ºÀ¸¿Õܹ⳰ԾåÈé´â¤Î1Îã
ü⸶¡¡À¯Íø¡¤¿å¾ë¤Þ¤µ¤ß¡¤¿ûÌî¡¡ÃÒɧ¡¤Á°Åľ¼ÂÀϺ¡¤µÆÃÓ¡¡´îÇî

¾ÉÎã

·Ðµ¤´É»Ù¶ÀŪ¤Ë¿ÇÃÇ¡¦ÀÚ½ü¤·ÆÀ¤¿µ¤´É»ÙÆâÆð¹üÀ­²á¸í¼ð¤Î1Îã
¶âÅÄ¡¡¡¡·Ë¡¤³­ÅÄ¡¡Í¦²ð¡¤²ÃÆ£¡¡¿¿¿Í¡¤ÎëÌÚÀ¶°ìϺ¡¤Ã漡¡Î´°ì¡¤¿ÜÅÄ¡¡Î´Ê¸

¾ÉÎã

¥¦¥³¥ó¤Ë¤è¤ëÌôºÞÀ­Çپ㳲¤Î1Îã
ÈÄ°æ¿¿Íü»Ò¡¤½Å±Ê¡¡Éðɧ¡¤µÜºê¡¡¼þÌ顤ÁýÌî¡¡ÃҾϡ¤Èª¡¡¡¡Àµ¹­¡¤ÌçÅÄ¡¡½ß°ì

¾ÉÎã

PET/CT¤ÇÇÙ´â½Ñ¸åºÆȯ¤¬µ¿¤ï¤ì¤¿¥ê¥Ý¥¤¥ÉÇÙ±ê¤Î1Îã
À¾²­¡¡½Óɧ¡¤¸¶¸ý¡¡¿ð¼ù¡¤»°¿¹¡¡Í§Ì÷¡¤Â¼ÌÚ¡¡·Ä»Ò¡¤´ØÀî¡¡¡¡½¡¡¤´Øë¡¡½¼¹¸

¾ÉÎã

Cyclin-dependent kinase 4/6Á˳²Ìô¥¢¥Ù¥Þ¥·¥¯¥ê¥Ö¤Ë¤è¤ëÌôºÞÀ­´Ö¼ÁÀ­ÇÙ±ê¤Î1Îã
ÎëÌÚ¡¡Ä¾¿Î¡¤ÃæÅè¡¡¼£É§¡¤Ãæ·§¡¡Âº»Î

¾ÉÎã

˵µ¤´Éǹ˦¤òÍ­¤·¡¤µ¤´É»Ù¶À¸¡ºº¸å¤Ë½Ä³Öµ¤¼ð¤ò¤­¤¿¤·¤¿1Îã
°ËÆ£¡¡ÆÁÌÀ¡¤Èø²¼¡¡¹ë¿Í¡¤ËåÈø¡¡ÈþΤ¡¤Á¥ÀС¡Ë®É§¡¤»°¶Ì¡¡¹¯¹¬¡¤±üºê¡¡¡¡·ò

¾ÉÎã

¥Ñ¥¹¥Ä¥ì¥é¸ÆµÛ´ï´¶À÷¾É¤ò¹çÊ»¤·¤¿¥¢¥ì¥ë¥®¡¼À­µ¤´É»ÙÇÙ¿¿¶Ý¾É¤Î1Îã
Èø²¼¡¡¹ë¿Í¡¤üⶶ¡¡Ã£µª¡¤°ËÆ£¡¡ÆÁÌÀ¡¤ËåÈø¡¡ÈþΤ¡¤Á¥ÀС¡Ë®É§¡¤±üºê¡¡¡¡·ò

¾ÉÎã

ÇÙ´âÌȱּ£ÎÅÃæ¤Ëȯ¾É¤·¤¿¥ê¥¦¥Þ¥ÁÀ­Â¿È¯¶ÚÄ˾ɤοÇÃÇɾ²Á¤ËPET¤¬Í­ÍѤǤ¢¤Ã¤¿1Îã
Ãæ±ö²°ÆóϺ¡¤Î¤±ò¡¡Ì¡¤Ã«Àî¡¡·ò¸ç¡¤È¬ÌÚ¡¡Êþ»Ò¡¤Æ²ÖÖ¡¡Íΰ졤Å층¡¡°ì¹¸

¾ÉÎã

¥¯¥âËì²¼½Ð·ì¤ò½éȯ¾É¾õ¤È¤·¤Æȯ¾É¤·¤¿¹¥»ÀµåÀ­Â¿È¯·ì´É±êÀ­Æù²ê¼ð¾É¤Î1Îã
Æêùõ¡¡¡¡Í£¡¤¹â»³¡¡Íµ²ð¡¤¾®ÎÓ±ÑΤ²Â¡¤Ã漡¡µ®»Ö¡¤±×ÅÄ¡¡¡¡·ò¡¤¾±ÅÄ¡¡¹À¹¯

¾ÉÎã

·ìÀò·ÁÀ®¤Ë¤è¤ê¤±Æ¸ú²Ì¤Î¸º¼å¤òǧ¤á¤¿ÇÙ·ì´ÉÉÂÊѤ¬¶»¹ÐÆâÀüÇˤ·¤¿1Îã
±üËÜ¡¡¡¡¾÷¡¤»³¸ý¡¡³ÐÇ¶ûë¡¡¡¡·Ë¡¤´äËÜ¡¡Çî»Ö¡¤²¬ÅÄ¡¡¼é¿Í¡¤ÉþÉô¡¡¡¡ÅÐ

¾ÉÎã

HTLV-1´ØÏ¢µ¤´É»ÙÇÙ¼À´µ¤ÎĹ´ü´Ñ»¡Îã
¶¶ËÜ·òÂÀϺ¡¤¾¾ËÜ¡¡µ×»Ò¡¤¹õß·¡¡¡¡³Ø¡¤É©ß·¡¡Êý¾¡¡¤¹âÀÞ¡¡¹¸»Ë¡¤Ê¿°æ¡¡Ë­Çî

Letter to the Editor
Response to Letter to the Editor

COPD¼£ÎŤˤª¤±¤ëSABA¥¢¥·¥¹¥È¥æ¡¼¥¹¤ÎÌäÂêÅÀ
»ûËÜ¡¡¿®»Ì

¾¦ÉÊ¥³¡¼¥É : jrs_2000-94
²Á³Ê : 6,435±ß¡ÊÀǹþ¡Ë
¿ôÎÌ
 
²ñ·×½ñÎबɬÍפÊÊý¤Ï¤³¤Á¤é

¤«¤´¤ËÆþ¤ì¤ë ¤¹¤°¤Ë¹ØÆþ
  • ¤ªµ¤¤ËÆþ¤ê¥ê¥¹¥È
  • ¾¦ÉʤˤĤ¤¤Æ¤ÎÌ䤤¹ç¤ï¤»

¥Ú¡¼¥¸¥È¥Ã¥×¤Ø